188 related articles for article (PubMed ID: 32210091)
1. LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications.
Ben-Ami E; Perret R; Huang Y; Courgeon F; Gokhale PC; Laroche-Clary A; Eschle BK; Velasco V; Le Loarer F; Algeo MP; Purcell J; Demetri GD; Italiano A
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32210091
[TBL] [Abstract][Full Text] [Related]
2. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW; Tanlimco SG; Hickson J; Fox M; Sho M; Durkin L; Uziel T; Powers R; Foster K; McGonigal T; Kumar S; Samayoa J; Zhang D; Palma JP; Mishra S; Hollenbaugh D; Gish K; Morgan-Lappe SE; Hsi ED; Chao DT
Cancer Res; 2018 Jul; 78(14):4059-4072. PubMed ID: 29764866
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
Demetri GD; Luke JJ; Hollebecque A; Powderly JD; Spira AI; Subbiah V; Naumovski L; Chen C; Fang H; Lai DW; Yue H; Polepally AR; Purcell JW; Robinson R; Sharma P; Allison JP; Tolcher A; Villalobos VM
Clin Cancer Res; 2021 Jul; 27(13):3556-3566. PubMed ID: 33820780
[TBL] [Abstract][Full Text] [Related]
4. ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P; Roth ME; Wang Y; Zhang W; Gill JB; Harrison DJ; Teicher B; Erickson S; Gatto G; Smith MA; Kolb EA; Gorlick R
Mol Cancer Ther; 2021 Mar; 20(3):535-540. PubMed ID: 33298592
[TBL] [Abstract][Full Text] [Related]
5. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.
Slemmons KK; Mukherjee S; Meltzer P; Purcell JW; Helman LJ
Pediatr Blood Cancer; 2021 Feb; 68(2):e28771. PubMed ID: 33063919
[TBL] [Abstract][Full Text] [Related]
6. Exploiting LRRC15 as a Novel Therapeutic Target in Cancer.
Ray U; Pathoulas CL; Thirusangu P; Purcell JW; Kannan N; Shridhar V
Cancer Res; 2022 May; 82(9):1675-1681. PubMed ID: 35260879
[TBL] [Abstract][Full Text] [Related]
7. Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer.
Ray U; Jung DB; Jin L; Xiao Y; Dasari S; Sarkar Bhattacharya S; Thirusangu P; Staub JK; Roy D; Roy B; Weroha SJ; Hou X; Purcell JW; Bakkum-Gamez JN; Kaufmann SH; Kannan N; Mitra AK; Shridhar V
Cancer Res; 2022 Mar; 82(6):1038-1054. PubMed ID: 34654724
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
[TBL] [Abstract][Full Text] [Related]
9. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
10. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
11. LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer.
Zhu X; You S; Du X; Song K; Lv T; Zhao H; Yao Q
BMC Med Genomics; 2023 Jan; 16(1):10. PubMed ID: 36653841
[TBL] [Abstract][Full Text] [Related]
12. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
Anderson MG; Zhang Q; Rodriguez LE; Hecquet CM; Donawho CK; Ansell PJ; Reilly EB
BMC Cancer; 2021 Jun; 21(1):681. PubMed ID: 34107902
[TBL] [Abstract][Full Text] [Related]
13. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
[TBL] [Abstract][Full Text] [Related]
14. Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.
Van Renterghem B; Wozniak A; Castro PG; Franken P; Pencheva N; Sciot R; Schöffski P
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886842
[TBL] [Abstract][Full Text] [Related]
15. LRRC15
Krishnamurty AT; Shyer JA; Thai M; Gandham V; Buechler MB; Yang YA; Pradhan RN; Wang AW; Sanchez PL; Qu Y; Breart B; Chalouni C; Dunlap D; Ziai J; Elstrott J; Zacharias N; Mao W; Rowntree RK; Sadowsky J; Lewis GD; Pillow TH; Nabet BY; Banchereau R; Tam L; Caothien R; Bacarro N; Roose-Girma M; Modrusan Z; Mariathasan S; Müller S; Turley SJ
Nature; 2022 Nov; 611(7934):148-154. PubMed ID: 36171287
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma.
Cui J; Dean D; Wei R; Hornicek FJ; Ulmert D; Duan Z
J Orthop Res; 2020 Nov; 38(11):2362-2372. PubMed ID: 32902907
[TBL] [Abstract][Full Text] [Related]
17. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both
Wang J; Anderson MG; Oleksijew A; Vaidya KS; Boghaert ER; Tucker L; Zhang Q; Han EK; Palma JP; Naumovski L; Reilly EB
Clin Cancer Res; 2017 Feb; 23(4):992-1000. PubMed ID: 27573171
[No Abstract] [Full Text] [Related]
18. ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
Chang CA; Emberley E; D'Souza AL; Zhao W; Cosgrove C; Parrish KE; Mitra D; Payson E; Oleksijew A; Ellis P; Rodriguez L; Duggan R; Hrusch C; Lasko L; Assaily W; Zheng P; Liu W; Hernandez A; McCarthy K; Zhang Z; Rha G; Cao Z; Li Y; Perng O; Campbell J; Zhang G; Curran TS; Bruncko M; Marvin CC; Hobson AD; McPherson M; Uziel T; Pysz MA; Zhao X; Bankovich A; Hayflick J; McDevitt M; Freise KJ; Morgan-Lappe S; Purcell JW
Blood; 2024 May; ():. PubMed ID: 38701407
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
[TBL] [Abstract][Full Text] [Related]
20. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
